Citalopram-induced hallucinations and delusions in a young adult

Capaldi, Vincent F.; Carr, Russell B.

doi:10.1016/j.genhosppsych.2010.07.008

Cited by 20 publications

(12 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar findings were seen for the centrally working sympathomimetics. Reports on hallucinations in association with SSRI therapy as well as with the centrally working sympathomimetic drugs have been published previously, and awareness of this unusual but potentially severe adverse reaction is important because it may be mistaken for a symptom of the disease.…”

Section: Discussionmentioning

confidence: 99%

Psychiatric adverse drug reactions reported during a 10‐year period in the Swedish pediatric population

Bygdell

Brunlöf

Wallerstedt

et al. 2011

Pharmacoepidemiology and Drug

View full text Add to dashboard Cite

Psychiatric ADRs in the pediatric population have been reported for a wide range of reactions and drugs and display age and sex differences including a higher number of suicidal reactions in boys. An association was seen between serious reactions and off-label drug use. Further studies are needed to elucidate safety aspects of unlicensed drugs and drugs used off-label and whether there are differences in children's susceptibility to develop ADRs.

show abstract

Section: Discussionmentioning

confidence: 99%

Psychiatric adverse drug reactions reported during a 10‐year period in the Swedish pediatric population

Bygdell

Brunlöf

Wallerstedt

et al. 2011

Pharmacoepidemiology and Drug

View full text Add to dashboard Cite

show abstract

“…This also indicates that using a pure depression scale as outcome measure in PD may result in an overestimation of the clinical benefit of antidepressants, because the psychotic symptoms, which respond less to antidepressants, are not taken properly into account. A related reason for preferring a scale covering both depressive and psychotic symptoms is that it will be more likely to detect potential worsening in psychotic symptoms during treatment, which has indeed been reported previously for the selective serotonin reuptake inhibitors in PD (Bourgeois, et al, 1998; Capaldi and Carr, 2010; Narayan, et al, 1995; Popli, et al, 1997). This clinical phenomenon is unlikely to be captured in full by the HAM-D 17 and HAM-D 6 .…”

Section: Discussionmentioning

confidence: 78%

Measuring treatment response in psychotic depression: The Psychotic Depression Assessment Scale (PDAS) takes both depressive and psychotic symptoms into account

Østergaard

Meyers

Flint

et al. 2014

Journal of Affective Disorders

View full text Add to dashboard Cite

Background There is no established psychometric instrument dedicated to the measurement of severity in psychotic depression (PD). The aim of this study was to investigate whether a new composite rating scale, the Psychotic Depression Assessment Scale (PDAS), covering both the psychotic and the depressive domains of PD, could detect differences in effect between two psychopharmacological treatment regimens. Methods We reanalyzed the data from the Study of Pharmacotherapy of Psychotic Depression (STOP-PD), which compared the effect of Olanzapine+Sertraline (n=129) versus Olanzapine+Placebo (n=130). The response to the two regimens was compared using both a mixed effects model and effect size statistics on the total scores of three rating scales: the 17-item Hamilton Depression Rating Scale (HAM-D17), its 6-item melancholia subscale (HAM-D6), and the 11-item PDAS consisting of the HAM-D6 plus five items from the Brief Psychiatric Rating Scale covering psychotic symptoms. Results According to both statistical approaches, the PDAS, the HAM-D17 and the HAM-D6 were all able to detect significant differences in treatment effect between Olanzapine+Sertraline and Olanzapine+Placebo (Olanzapine+Sertraline being superior). Notably, 45% of the trial participants were at least “probable psychotic” at their last assessment in the trial. Limitations The STOP-PD was not designed specifically to answer the research questions of the present study. Conclusions The Psychotic Depression Assessment Scale (PDAS) is a sensitive measure of treatment response in PD. The fact that 45% of the patients still experienced psychotic symptoms at their last trial assessment emphasizes the need to include items pertaining to psychotic symptoms in rating scales for PD.

show abstract

“…Although it is unclear whether paroxetine tends to induce nightmares, any drugs associated with norepinephrine, serotonin, or dopamin can induce nightmares 3 . Indeed, there are a number of reports suggesting the hallucinogenic potential of SSRIs 4–20 . A number of patients who have taken SSRIs combined with other neuroactive drugs or have had organic brain dysfunction have presented with hallucinations 4,5,7–10,15–19 .…”

Section: Discussionmentioning

confidence: 99%

A case of serial nightmares and oneiroid state under paroxetine for senile depression

Kobayashi

Yamauchi

2012

Psychogeriatrics

View full text Add to dashboard Cite

We report on rare side effects of paroxetine. A 67‐year‐old female patient who had been suffering from prolonged depression for over a year but had not received appropriate treatment was administered 20‐mg paroxetine daily. However, the patient required hospital admission after 16 days because of behavioural disturbances and delusions that she was being chased by evil persons from a religious group. The delusions were ultimately confirmed to be serial nightmares and an oneiroid state. The nightmares gradually disappeared following discontinuation of paroxetine. The Adverse Drug Reaction Probability Scale showed a score of 6 (probable). Reports on paroxetine‐induced nightmares are rare, and there is a possibility that, in this case, parexetine caused the nightmares in association with depression and assumed underlying brain dysfunction due to ageing.

show abstract

Citalopram-induced hallucinations and delusions in a young adult

Cited by 20 publications

References 8 publications

Psychiatric adverse drug reactions reported during a 10‐year period in the Swedish pediatric population

Psychiatric adverse drug reactions reported during a 10‐year period in the Swedish pediatric population

Measuring treatment response in psychotic depression: The Psychotic Depression Assessment Scale (PDAS) takes both depressive and psychotic symptoms into account

A case of serial nightmares and oneiroid state under paroxetine for senile depression

Contact Info

Product

Resources

About